Tags

Type your tag names separated by a space and hit enter

A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China.
Chin Med J (Engl). 2003 Jan; 116(1):44-8.CM

Abstract

OBJECTIVE

To evaluate the efficacy and safety of oseltamivir phosphate as treatment for naturally acquired influenza infection.

METHODS

This study was conducted as a double-blind, randomized, placebo-controlled, multicenter trial during the influenza epidemic season from January to April 2001 at 7 centers in China. A total of 478 adults without other medical history, aged 18 to 65 years, were enrolled into the study. All subjects demonstrated febrile respiratory illness of no more than 36 hours' duration with a temperature of 37.8 degrees C or more plus at least two of the following symptoms: coryza/nasal congestion, sore throat, cough, myalgia/muscles aches and pain, fatigue, headache or chills/sweats. Individuals were randomized into either the oseltamivir phosphate or placebo group with identical-looking capsules. Either oral oseltamivir phosphate, 75 mg twice daily, or placebo was administered to the subjects for 5 days.

RESULTS

A total of 451 individuals were analyzed for efficacy as the intent-to-treat population (ITT) (216 oseltamivir and 235 placebo) and 273 individuals were identified as influenza-infected through laboratory test, who were then defined as the intent-to-treat infected population (ITTI) (134 oseltamivir and 139 placebo). Four hundred and fifty nine individuals were included in the safety analysis. In the ITTI population, the cumulative alleviation proportion of oseltamivir group was significantly higher than that of the placebo group (P = 0.0466)). The median duration of illness was 91.6 h [95% confidence interval (CI) = 80.2 - 101.3 h] in the oseltamivir group and 95 h (95% CI = 84.5 - 105.3 h) in the placebo group. The median area under the curve of decreased total score was significantly higher in the oseltamivir group than in the placebo group, 1382.9 and 1236.7 score-hours, respectively (P = 0.0196). For the ITT population, similar results were observed. Adverse events (AE) were similarly reported in both the oseltamivir group and the placebo group. The main adverse events following test drug were gastrointestinal symptoms, neurological symptoms and rashes.

CONCLUSION

Oseltamivir was effective and well tolerated as treatment of early naturally acquired influenza.

Authors+Show Affiliations

Li L
Department of Respiratory Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.
Cai B
No affiliation info available
Wang M
No affiliation info available
Zhu Y
No affiliation info available

MeSH

AcetamidesAdultAgedAntiviral AgentsDouble-Blind MethodEnzyme InhibitorsFemaleHumansInfluenza, HumanMaleMiddle AgedNeuraminidaseOseltamivir

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

12667386

Citation

Li, Longyun, et al. "A Double-blind, Randomized, Placebo-controlled Multicenter Study of Oseltamivir Phosphate for Treatment of Influenza Infection in China." Chinese Medical Journal, vol. 116, no. 1, 2003, pp. 44-8.
Li L, Cai B, Wang M, et al. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chin Med J (Engl). 2003;116(1):44-8.
Li, L., Cai, B., Wang, M., & Zhu, Y. (2003). A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chinese Medical Journal, 116(1), 44-8.
Li L, et al. A Double-blind, Randomized, Placebo-controlled Multicenter Study of Oseltamivir Phosphate for Treatment of Influenza Infection in China. Chin Med J (Engl). 2003;116(1):44-8. PubMed PMID: 12667386.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. AU - Li,Longyun, AU - Cai,Boqiang, AU - Wang,Mengzhao, AU - Zhu,Yuanjue, PY - 2003/4/2/pubmed PY - 2003/4/16/medline PY - 2003/4/2/entrez SP - 44 EP - 8 JF - Chinese medical journal JO - Chin Med J (Engl) VL - 116 IS - 1 N2 - OBJECTIVE: To evaluate the efficacy and safety of oseltamivir phosphate as treatment for naturally acquired influenza infection. METHODS: This study was conducted as a double-blind, randomized, placebo-controlled, multicenter trial during the influenza epidemic season from January to April 2001 at 7 centers in China. A total of 478 adults without other medical history, aged 18 to 65 years, were enrolled into the study. All subjects demonstrated febrile respiratory illness of no more than 36 hours' duration with a temperature of 37.8 degrees C or more plus at least two of the following symptoms: coryza/nasal congestion, sore throat, cough, myalgia/muscles aches and pain, fatigue, headache or chills/sweats. Individuals were randomized into either the oseltamivir phosphate or placebo group with identical-looking capsules. Either oral oseltamivir phosphate, 75 mg twice daily, or placebo was administered to the subjects for 5 days. RESULTS: A total of 451 individuals were analyzed for efficacy as the intent-to-treat population (ITT) (216 oseltamivir and 235 placebo) and 273 individuals were identified as influenza-infected through laboratory test, who were then defined as the intent-to-treat infected population (ITTI) (134 oseltamivir and 139 placebo). Four hundred and fifty nine individuals were included in the safety analysis. In the ITTI population, the cumulative alleviation proportion of oseltamivir group was significantly higher than that of the placebo group (P = 0.0466)). The median duration of illness was 91.6 h [95% confidence interval (CI) = 80.2 - 101.3 h] in the oseltamivir group and 95 h (95% CI = 84.5 - 105.3 h) in the placebo group. The median area under the curve of decreased total score was significantly higher in the oseltamivir group than in the placebo group, 1382.9 and 1236.7 score-hours, respectively (P = 0.0196). For the ITT population, similar results were observed. Adverse events (AE) were similarly reported in both the oseltamivir group and the placebo group. The main adverse events following test drug were gastrointestinal symptoms, neurological symptoms and rashes. CONCLUSION: Oseltamivir was effective and well tolerated as treatment of early naturally acquired influenza. SN - 0366-6999 UR - https://www.unboundmedicine.com/medline/citation/12667386/A_double_blind_randomized_placebo_controlled_multicenter_study_of_oseltamivir_phosphate_for_treatment_of_influenza_infection_in_China_ DB - PRIME DP - Unbound Medicine ER -